Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group. Russell-Jones D, et al. Among authors: hanefeld m. Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210563 Free PMC article. Clinical Trial.
Review of approved pioglitazone combinations for type 2 diabetes.
Forst T, Hanefeld M, Pfützner A. Forst T, et al. Among authors: hanefeld m. Expert Opin Pharmacother. 2011 Jul;12(10):1571-84. doi: 10.1517/14656566.2011.567266. Epub 2011 Jun 4. Expert Opin Pharmacother. 2011. PMID: 21639813 Review.
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Hanefeld M, et al. Cardiovasc Diabetol. 2011 Jul 14;10:65. doi: 10.1186/1475-2840-10-65. Cardiovasc Diabetol. 2011. PMID: 21756323 Free PMC article. Clinical Trial.
Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Hanefeld M, Forst T. Hanefeld M, et al. Lancet. 2010 Jun 26;375(9733):2196-8. doi: 10.1016/S0140-6736(10)60749-0. Lancet. 2010. PMID: 20609956 No abstract available.
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
Pfützner A, Hanefeld M, Dekordi LA, Müller J, Kleine I, Fuchs W, Forst T. Pfützner A, et al. Among authors: hanefeld m. J Diabetes Sci Technol. 2011 Jul 1;5(4):989-98. doi: 10.1177/193229681100500422. J Diabetes Sci Technol. 2011. PMID: 21880242 Free PMC article. Clinical Trial.
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators. Rosenstock J, et al. Among authors: hanefeld m. Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15. Diabetes Care. 2016. PMID: 27527848 Clinical Trial.
399 results